REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH FOLLICULAR LYMPHOMA IN KOREA: COMPARISONS BY POD24 STATUS USING NATIONWIDE CLAIMS DATA
Author(s)
Ha-Jun Song1, Swan Kwon, PharmD2, Dong-Won Kang, PhD3, EUI-KYUNG LEE, RPh, PhD4.
1Student, Sungkyunkwan University, Suwon, Korea, Republic of, 2sungkyunkwan university, Seoul, Korea, Republic of, 3Ajou University, College of Pharmacy, Suwon, Korea, Republic of, 4sungkyunkwan university, Suwon, Korea, Republic of.
1Student, Sungkyunkwan University, Suwon, Korea, Republic of, 2sungkyunkwan university, Seoul, Korea, Republic of, 3Ajou University, College of Pharmacy, Suwon, Korea, Republic of, 4sungkyunkwan university, Suwon, Korea, Republic of.
OBJECTIVES: Follicular lymphoma (FL) is characterized by frequent relapse and heterogeneous treatment strategies. In particular, patients who experience disease progression within 24 months (POD24) after initial treatment are known to have a poor prognosis, yet treatment patterns and unmet needs in this high-risk population remain insufficiently characterized. This study aimed to compare real-world treatment patterns according to POD24 status among patients with FL in Korea.
METHODS: This retrospective cohort study used Korean nationwide claims data to identify adults newly diagnosed with FL between 2015 and 2019, with follow-up through July 2024. Patients initiating second-line treatment within 24 months of first-line treatment initiation were classified as the POD24 group, and those initiating later as the non-POD24 group. Treatment lines through third-line therapy were identified using an algorithm informed by Korean reimbursement criteria and clinical guidelines, and time to next treatment was assessed between successive lines.
RESULTS: Among 736 patients who initiated first-line treatment, 162 (22.0%) initiated second-line therapy; of these, 87 (53.7%) were classified as the POD24 group and 75 (46.3%) as the non-POD24 group. The most common second-line regimens were ICE (24.1%) and R-CHOP (17.2%) in the POD24 group, compared with rituximab monotherapy (22.7%) and obinutuzumab plus bendamustine (17.3%) in the non-POD24 group. Overall, 68 patients initiated third-line therapy, corresponding to 49.4% of the POD24 group and 33.3% of the non-POD24 group. The median time from initiation of second-line therapy to initiation of third-line therapy was shorter in the POD24 group than in the non-POD24 group (231 days vs 381 days).
CONCLUSIONS: Real-world treatment patterns differed according to POD24 status among patients with FL in Korea. Patients in the POD24 group showed more frequent progression to third-line therapy and a shorter time to subsequent treatment, highlighting the substantial treatment burden and unmet need for optimized treatment strategies in this high-risk population.
METHODS: This retrospective cohort study used Korean nationwide claims data to identify adults newly diagnosed with FL between 2015 and 2019, with follow-up through July 2024. Patients initiating second-line treatment within 24 months of first-line treatment initiation were classified as the POD24 group, and those initiating later as the non-POD24 group. Treatment lines through third-line therapy were identified using an algorithm informed by Korean reimbursement criteria and clinical guidelines, and time to next treatment was assessed between successive lines.
RESULTS: Among 736 patients who initiated first-line treatment, 162 (22.0%) initiated second-line therapy; of these, 87 (53.7%) were classified as the POD24 group and 75 (46.3%) as the non-POD24 group. The most common second-line regimens were ICE (24.1%) and R-CHOP (17.2%) in the POD24 group, compared with rituximab monotherapy (22.7%) and obinutuzumab plus bendamustine (17.3%) in the non-POD24 group. Overall, 68 patients initiated third-line therapy, corresponding to 49.4% of the POD24 group and 33.3% of the non-POD24 group. The median time from initiation of second-line therapy to initiation of third-line therapy was shorter in the POD24 group than in the non-POD24 group (231 days vs 381 days).
CONCLUSIONS: Real-world treatment patterns differed according to POD24 status among patients with FL in Korea. Patients in the POD24 group showed more frequent progression to third-line therapy and a shorter time to subsequent treatment, highlighting the substantial treatment burden and unmet need for optimized treatment strategies in this high-risk population.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HSD113
Topic
Health Service Delivery & Process of Care, Real World Data & Information Systems
Disease
Oncology